Matching articles for "daunorubicin"
Issue 1750 · March 16, 2026
Ziftomenib (Komzifti) for Acute Myeloid Leukemia (online only)

Ziftomenib ( Komzifti – Kura), an oral menin inhibitor, has been approved by the FDA for treatment of adults with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1)…

Med Lett Drugs Ther. 2026 Mar 16; 68(1750):e48-9 doi:10.58347/tml.2026.1750e
Ziftomenib ( Komzifti – Kura), an oral menin inhibitor, has been approved by the FDA for treatment of adults with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation who have no satisfactory alternative treatment options. It is the second oral menin inhibitor to be approved in the US for this indication; revumenib (Revuforj) was approved in October 2025 for use in patients ≥1 year old.
Issue 1687 · October 16, 2023
Quizartinib (Vanflyta) for Acute Myeloid Leukemia (online only)

The FDA has approved the oral kinase inhibitor quizartinib ( Vanflyta – Daiichi Sankyo) for use in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as…

Med Lett Drugs Ther. 2023 Oct 16; 65(1687):e169-70 doi:10.58347/tml.2023.1687d
The FDA has approved the oral kinase inhibitor quizartinib ( Vanflyta – Daiichi Sankyo) for use in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy in adults with FLT3 internal tandem duplication (ITD)-positive, newly-diagnosed acute myeloid leukemia (AML).
Issue 1543 · March 26, 2018 Free
In Brief: Two New Drugs for AML (online only)

The FDA has approved two new drugs for treatment of specific subtypes of acute myeloid leukemia (AML). Vyxeos (Jazz Pharmaceuticals) is a liposomal fixed-dose combination of daunorubicin and cytarabine, the…

Med Lett Drugs Ther. 2018 Mar 26; 60(1543):e56
The FDA has approved two new drugs for treatment of specific subtypes of acute myeloid leukemia (AML). Vyxeos (Jazz Pharmaceuticals) is a liposomal fixed-dose combination of daunorubicin and cytarabine, the standard drugs used for induction treatment of AML. It is approved for induction and consolidation treatment in adults with newly diagnosed chemotherapy- or radiation-related AML or AML with myelodysplasia-related changes. Patients with these subtypes of AML have a poor prognosis. The rationale for development of the combination was that nano-scale liposomal drug delivery vehicles prolong and maintain drug concentrations, resulting in increased efficacy in animal studies. 1 In a trial in 309 patients 60-75 years old with these subtypes of AML, median overall survival was significantly longer in those treated with the liposomal combination than in those treated with conventional daunorubicin and cytarabine (9.56 vs 5.95 months). Adverse effects of the liposomal combination were similar to those with the conventional formulations. 2 Enasidenib ( Idhifa – Celgene) is approved for treatment of adults with relapsed or refractory AML who have mutations in isocitrate dehydrogenase-2 (IDH2); these mutations occur in about 12% of patients with AML. The new drug inhibits mutant-IDH2 enzymes, which block cellular differentiation. In a single-arm trial of enasidenib in 239 such patients, the overall response rate was 40.3%, the median duration of response was 5.8 months, and median overall survival was 9.3 months. A complete remission was achieved in 34 patients (14%). The responses were associated with differentiation of the myeloblasts rather than individual cytotoxicity. Indirect hyperbilirubinemia without apparent liver toxicity (38%) and nausea (23%) were the most common adverse effects of enasidenib in clinical trials. A life-threatening "differentiation syndrome" that affected multiple organs occurred in 23 patients (10%); it generally responded to treatment with corticosteroids, but two patients died from the acute effects of leukocyte proliferation. 3 E J Feldman et al. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. J Clin Oncol 2011; 29:979. JE Lancet et al. Final results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML. J Clin Oncol 2016; 34:15 suppl 7000. EM Stein et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood 2017; 130:722. Download complete U.S. English article
Issue 1467 · April 27, 2015
Netupitant/Palonosetron (Akynzeo) for Chemotherapy-Induced Nausea and Vomiting

The FDA has approved Akynzeo (Helsinn/Eisai), an oral fixed-dose combination of the substance P/neurokinin 1 (NK 1 ) receptor antagonist netupitant and the serotonin-3 (5-HT 3 ) receptor antagonist…

Med Lett Drugs Ther. 2015 Apr 27; 57(1467):61-3
The FDA has approved Akynzeo (Helsinn/Eisai), an oral fixed-dose combination of the substance P/neurokinin 1 (NK 1 ) receptor antagonist netupitant and the serotonin-3 (5-HT 3 ) receptor antagonist palonosetron, for prevention of acute and delayed nausea and vomiting associated with cancer chemotherapy in adults. Akynzeo is the first product to combine drugs from these two classes. Palonosetron (Aloxi) is also available as a single agent for prevention of chemotherapy-induced and postoperative nausea and vomiting. Netupitant is the second substance P/NK 1 receptor antagonist to be approved in the US; aprepitant (Emend) was the first.
Issue 1162 · August 4, 2003
Aprepitant (Emend) for Prevention of Nausea and Vomiting Due to Cancer Chemotherapy

Aprepitant ( Emend - Merck), the first substance P/neurokinin 1 (NK 1 ) receptor antagonist to be approved by the FDA, is now available for oral use with corticosteroids and selective serotonin (5-HT 3 )…

Med Lett Drugs Ther. 2003 Aug 4; 45(1162):62-3
Aprepitant ( Emend - Merck), the first substance P/neurokinin 1 (NK 1 ) receptor antagonist to be approved by the FDA, is now available for oral use with corticosteroids and selective serotonin (5-HT 3 ) receptor antagonists to prevent nausea and vomiting caused by highly emetogenic anticancer drugs such as cisplatin.
Issue 7 · March 1, 2003
Drugs of Choice for Cancer

The tables in this article list drugs used for treatment of cancer in the USA and Canada and their major adverse effects. The choice of drugs in Table I is based on the opinions of Medical Letter consultants.…

Treat Guidel Med Lett. 2003 Mar; 1(7):41-52
The tables in this article list drugs used for treatment of cancer in the USA and Canada and their major adverse effects. The choice of drugs in Table I is based on the opinions of Medical Letter consultants. Some drugs are listed for indications for which they have not been approved by the US Food and Drug Administration. In some cases, such as elderly patients or those with many co-morbid illnesses, the regimen of choice might not be suitable. For many of the cancers listed, surgery and/or radiation therapy may be the treatment of choice or may also be part of the management. Anticancer drugs and their adverse effects are listed in Table II on page 46. A partial list of brand names appears on page 52.
Issue 1087 · September 18, 2000
Drugs of Choice For Cancer Chemotherapy (combined issue 1087-1088)

The tables in this article list drugs used for treatment of cancer in the USA and Canada. The choices of drugs in Table 1 is based on the opinions of Medical Letter consultants. Some drugs are listed for…

Med Lett Drugs Ther. 2000 Sep 18; 42(1087):83-92
The tables in this article list drugs used for treatment of cancer in the USA and Canada. The choices of drugs in Table 1 is based on the opinions of Medical Letter consultants. Some drugs are listed for indications for which they have not been approved by the US Food and Drug Administration. For many of the cancers listed, surgery and/or radiation therapy are also part of the management of the disease.
Issue 944 · March 17, 1995
Pegaspargase for Acute Lymphoblastic Leukemia

Pegaspargase (peg as par jase; PEG-L-asparaginase; Oncaspar - Rh ne-Poulenc Rorer), a polyethylene glycol (PEG) conjugate of L-asparaginase, has been approved by the US Food and Drug Administration for…

Med Lett Drugs Ther. 1995 Mar 17; 37(944):23-4
Pegaspargase (peg as par jase; PEG-L-asparaginase; Oncaspar - Rh ne-Poulenc Rorer), a polyethylene glycol (PEG) conjugate of L-asparaginase, has been approved by the US Food and Drug Administration for treatment of acute lymphoblastic leukemia (ALL), the most common malignancy of childhood. The new drug is recommended only for patients who have had allergic reactions to asparaginase. Asparaginase is available commercially as Elspar, which is derived from Escherichia coli. A formulation derived from Erwinia chrysanthemi is available on an investigational basis (Ogden Bioservices, 301-762-0069). Some patients who have had allergic reactions to E. coli asparaginase can tolerate Erwinia asparaginase.
Issue 912 · December 24, 1993
Drugs for Vomiting Caused by Cancer Chemotherapy

Several currently available antiemetic drugs can prevent vomiting caused by cancer chemotherapy. Anticancer drugs that cause vomiting are listed in the table below.

Med Lett Drugs Ther. 1993 Dec 24; 35(912):124-6
Several currently available antiemetic drugs can prevent vomiting caused by cancer chemotherapy. Anticancer drugs that cause vomiting are listed in the table below.
Issue 883 · November 13, 1992
Teniposide for Acute Lymphoblastic Leukemia

Teniposide (ten i poe' side; VM 26; Vumon - Bristol), an anticancer drug that has been under investigation in the USA for 20 years, has now been approved for use in combination induction treatment of…

Med Lett Drugs Ther. 1992 Nov 13; 34(883):105-6
Teniposide (ten i poe' side; VM 26; Vumon - Bristol), an anticancer drug that has been under investigation in the USA for 20 years, has now been approved for use in combination induction treatment of refractory acute lymphoblastic leukemia (ALL) in children. A semisynthetic derivative of podophyllotoxin, teniposide is chemically related to etoposide ( VePesid - Medical Letter, 26:48, 1984).
Issue 852 · September 6, 1991
Idarubicin

Idarubicin hydrochloride ( Idamycin - Adria), an anthracycline structurally related to daunorubicin ( Cerubidine , and others) and doxorubicin ( Adriamycin , and others), was recently approved in the USA for…

Med Lett Drugs Ther. 1991 Sep 6; 33(852):84-5
Idarubicin hydrochloride ( Idamycin - Adria), an anthracycline structurally related to daunorubicin ( Cerubidine , and others) and doxorubicin ( Adriamycin , and others), was recently approved in the USA for treatment of acute myelogenous leukemia (AML) in adults.
Issue 852 · September 6, 1991
A Drug Prevention of Anthracycline-Induced Cardiac Toxicity

Recent studies have caused concern about cardiomyopathy associated with doxorubicin ( Adriamycin , and others), daunorubicin ( Cerubidine , and others), idarubicin ( Idamycin ), mitoxantrone ( Novantrone ),…

Med Lett Drugs Ther. 1991 Sep 6; 33(852):85-6
Recent studies have caused concern about cardiomyopathy associated with doxorubicin ( Adriamycin , and others), daunorubicin ( Cerubidine , and others), idarubicin ( Idamycin ), mitoxantrone ( Novantrone ), and related anthracycline or anthraquinone anticancer drugs. Dexrazoxane (ADR-529, ICRF-187 - Adria), a piperazine derivative of ethylenediaminetetraacetic acid (EDTA), is now under investigation for prevention of this drug-induced cardiomyopathy.
Issue 769 · July 1, 1988
Mitoxantrone

Mitoxantrone ( Novantrone - Lederle), a synthetic anthracene related to the anthracyclines doxorubicin ( Adriamycin ) and daunorubicin ( Cerubidine ), has now been marketed in the USA to be used in combination…

Med Lett Drugs Ther. 1988 Jul 1; 30(769):67-8
Mitoxantrone ( Novantrone - Lederle), a synthetic anthracene related to the anthracyclines doxorubicin ( Adriamycin ) and daunorubicin ( Cerubidine ), has now been marketed in the USA to be used in combination with other drugs for initial treatment of acute nonlymphocytic leukemia in adults.